Evaluation of a Personcentered Internet-based CBT Program for Stress, Anxiety and Depressive Symptoms in Patients With Cardiovascular Disease

Sponsor
University Hospital, Linkoeping (Other)
Overall Status
Not yet recruiting
CT.gov ID
NCT04726722
Collaborator
(none)
400
2
51.9

Study Details

Study Description

Brief Summary

To evaluate a nine-week adaptable and person-centred I-CBT program that can be directed towards stress, anxiety and depressive symptoms in persons with CVD.

Condition or Disease Intervention/Treatment Phase
  • Behavioral: internet-based cognitive behavioral theraphy
N/A

Detailed Description

All patients diagnosed as CVD (i.e. diagnosis Ischemia (ICD-code I20., I25.), Heart Failure (ICD-code I50., I42.) or Arrhythmia (ICD-code I48, I49, DF016) and who received care in the last 12 months at hospitals in the south-east of Sweden will be contacted by letter with information about the study.

Participants who are interested are invited to visit our website for more information, registration and provision of informed consent. After registration, participants will respond to questions about demographics, medical history, stress, anxiety and depressive symptoms on the website. Inclusion or exclusion will be assessed by a group consisting of a psychologist, cardiology specialist nurse and a psychiatry specialist nurse.

Before final inclusion and randomization eligible participants will be contacted for a telephone interview held by the study nurses.

Included (n=400) participants will, on our website (www.xxxxxx), complete the baseline study questionnaires and then be randomized according to a 2 x2 factorial design.

Study Design

Study Type:
Interventional
Anticipated Enrollment :
400 participants
Allocation:
Randomized
Intervention Model:
Factorial Assignment
Intervention Model Description:
2 x 22 x 2
Masking:
None (Open Label)
Primary Purpose:
Treatment
Official Title:
Evaluation of an Adaptable and Personcentered Internet-based CBT Program Aimed to Treat Stress, Anxiety and Depressive Symptoms in Patients With Cardiovascular Disease
Anticipated Study Start Date :
Feb 1, 2022
Anticipated Primary Completion Date :
Jun 1, 2024
Anticipated Study Completion Date :
Jun 1, 2026

Arms and Interventions

Arm Intervention/Treatment
Experimental: Design of the CBT treatment content

Patient determined CBT content (i.e. person-centered) vs. therapist determined I-CBT content

Behavioral: internet-based cognitive behavioral theraphy
When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules. Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

Experimental: Control of support and feedback

Patient-controlled support and feedback (person-centred) vs. therapist -controlled.

Behavioral: internet-based cognitive behavioral theraphy
When determining the content of the I-CBT program, the participants and therapist will be allowed to choose from a library of treatment modules. Therapist controlled support and feedback are given weekly and in a structured manner. Participants will be able to contact the therapist when support and feedback is desired

Outcome Measures

Primary Outcome Measures

  1. Change in stress from baseline to 9 weeks on the 10 item Perceived Stress Scale [From baseline to 9 weeks at the end of the intervention.]

    The 10-item Perceived Stress Scale is a valideted self-report of Stress. The instreument measures the degree to which individuals perceives their life situations as stressful. The 10 items are rated on a 5 point scale and higher scores means more stress

  2. Change in anxiety from baseline to 9 weeks on the 7-item Generalized Anxiety Disorder Scale. [From baseline to 9 weeks at the end of the intervention.]

    General Anxiety Disorder scale is validagted self-resport that measure symptoms of general anxiety during the last two weeks. The 7-items range from 0 (not bothered at all) to 3 (nearly every day). A higher score indicate more anxiety and the cut-off 5 suggests at least mild anxiety.

  3. Change in depressive symptoms from baseline to 9 weeks on the 9 item Patient Health Questionnaire. [From baseline to 9 weeks at the end of the intervention.]

    The 9-item Patient Health Questionnaire is a validated self-report that measure depressive symtpoms during the last two weeks. Each item is answered on a four graded scale where 0 means that the person not is affected and 3 where the person is affected several Days to almost every day. Higher numbers represents higher levels of depressive symptoms. A cut-off >5 represents at least mild depression.

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • age 18 years and above

  • treatment for cardiovascular disease (CVD) according to European Society of Cardiology guidelines

  • stable CVD (New York Heart Association class I-III) and not having been hospitalised for CVD in in the last four weeks.

  • stress (Perceived Stress Scale (PSS)-10>13 points) and/or

  • anxiety (i.e. General Anxiety Disorder Scale (GAD) ≥5 points) and/or

  • depressive symptoms (Patient Health Questionnaire-9 28 (PHQ-9) > 5 points)

Exclusion Criteria:
  • severe CVD (New York Heart Association classification IV) or another severe chronic life-threatening disease

  • severe stress, anxiety or depression assessed as requiring acute treatment

  • not being able to dedicate 3-4 hours per week to participate in the program

Contacts and Locations

Locations

No locations specified.

Sponsors and Collaborators

  • University Hospital, Linkoeping

Investigators

  • Principal Investigator: Peter Johansson, Ph.D, Department of Health, Medicine and Caring Sciences, Linkoping University

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Peter Johansson, Professor, Linkoeping University
ClinicalTrials.gov Identifier:
NCT04726722
Other Study ID Numbers:
  • 2020-00935
First Posted:
Jan 27, 2021
Last Update Posted:
Jan 27, 2021
Last Verified:
Jan 1, 2021
Individual Participant Data (IPD) Sharing Statement:
Undecided
Plan to Share IPD:
Undecided
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Keywords provided by Peter Johansson, Professor, Linkoeping University
Additional relevant MeSH terms:

Study Results

No Results Posted as of Jan 27, 2021